Welcome to The Ammon-Pinizzotto Center for Women’s Mental Health at MGH. Our Center, established in 1989, has been renamed following the generous gift from Carol Ammon and Dr. Marie Pinizzotto. These resources will be used to realize the overarching mission of the Center.
This website provides a range of current information including discussion of new research findings in women’s mental health and how such investigations inform day-to-day clinical practice. Despite the growing number of studies being conducted in women’s health, the clinical implications of such work are frequently controversial, leaving patients with questions regarding the most appropriate path to follow. Providing these resources to patients and their doctors so that individual clinical decisions can be made in a thoughtful and collaborative fashion dovetails with the mission of our Center.
All pregnant women ages 18-45 are eligible to enroll in the registry. The primary goal of this Registry is to determine the frequency of major malformations, such as heart defects, cleft lip, or neural tube defects, in infants exposed to atypical antipsychotics and antidepressants during pregnancy. We are currently seeking both controls and those being treated with atypical antipsychotics and/ or antidepressants. For more information, please visit this page, call 1-866-961-2388 or e-mail email@example.com.
Are you pregnant or planning a pregnancy? Do you feel depressed or have a history of depression? If you are less than 28 weeks pregnant or trying to conceive and have experienced depression now or in the past, you may be eligible to take part in a research study for the treatment of depression with a prenatal supplement. For more information, please visit this page, call Gina at 617-643-9284 or e-mail firstname.lastname@example.org.
Are you pregnant or planning to become pregnant? Do you have a history of depression? Do you want to lose weight or have a healthier lifestyle? You may be eligible to participate in a research study evaluating a new lifestyle intervention for weight loss. Participants will receive 10 sessions of therapy at no cost to you.
If you are interested in participating or would like additional information, please call Samantha at 617-643-2076.
Recognition and Characterization of Obsessive-Compulsive Symptoms in Postpartum Women:
Participation involves completing a survey that takes no more than 20 minutes: https://limesurvey.partners.org/limesurvey/index.php/463814?lang=en. For more information, if you have any questions or problems with this study please email the Principal Investigator (Dr. Baer) at email@example.com
The MGH Center for Women’s Mental Health
Perinatal and Reproductive Psychiatry Program
Simches Research Building
185 Cambridge St Suite 2200
Boston, MA 02114
To make an appointment:
Massachusetts General Hospital Clinical Program: (617) 724-7792
Location of appointments:
Wang Ambulatory Care Center, Massachusetts General Hospital
15 Parkman St., Floor 8
Boston, MA 02114-3117
May 24, 2017
It is clear that screening for perinatal depression substantially improves detection; however, screening alone does not appear to improve rates of treatment or outcomes. What we find is that many, if not most, women with perinatal depression do not receive adequate care. There appear to be many obstacles: stigma associated with mental illness, lack of ...Read more
May 22, 2017
There have long been concerns regarding the use of the anticonvulsant valproate (Depakote) during pregnancy. First trimester use of valproate has been associated with a 3-5% risk of neural tube defects, as well as an increased risk of other malformations affecting the heart, limbs, and genitals. Prenatal exposure to valproate may also result in lower ...Read more
May 17, 2017
PMDD or premenstrual dysphoric disorder has always been a bit of mystery. We explain that PMDD is triggered by changes in reproductive hormone levels, but when you look at hormone levels in women with PMDD, they do not differ significantly from the hormone levels of women without PMDD. Another question is why some women develop ...Read more
May 15, 2017
According to data from the 2002-2015 National Survey on Drug Use and Health, the prevalence of marijuana use was 3.8% in pregnant women (n=14,400), compared to 7.5% in nonpregnant women (n=395,600). The investigators observed that marijuana use was higher in the first trimester (6.4%) than in the second (3.3%) or third (1.8%) trimesters. Marijuana use ...Read more
May 10, 2017
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression. SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. This drug was initially under investigation for the treatment of refractory seizure disorders but it turned out to be a good antidepressant. The information we ...Read more
May 8, 2017
Maintenance treatment with a mood stabilizer during pregnancy can significantly reduce the risk of relapse in women with bipolar disorder; however, many of the mood stabilizers commonly used in this setting, including lithium and valproic acid, carry some degree of teratogenic risk. In contrast, lamotrigine (Lamictal) appears to be a much safer option for use ...Read more